IP Library Granted Patent US 8,361,476
Granted Patent B2
US 8,361,476 · App. 10/399,442 · Granted Jan 29, 2013

Vaccine composition comprising an antigen and a peptide having adjuvant properties

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,361,476
App. No.
10/399,442
Granted
Jan 29, 2013
Kind
B2
Abstract

The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R 1 —XZXZ N XZX—R 2 , whereby N is a whole number between 3 and 7, preferably 5, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and R 1 and R 2 are selected independantly one from the other from the group consisting of —H, —NH 2 , —COCH 3 , —COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X—R 2 may also be an amide, ester or thioester of the C-terminal amino acid residue, as well as the use of said peptide for the preparation of an adjuvant for enhancing the immune response to at least one antigen.

Claims (5)

1. A vaccine comprising at least one antigen and at least one peptide consisting of the sequence H—KLKLLLLLKLK—H (SEQ ID NO: 1).

2. The vaccine of claim 1 , further defined as comprising at least one further immune response stimulating substance.

3. The vaccine of claim 1 , further defined as comprising at least one immunostimulatory nucleic acid.

4. The vaccine of claim 3 , wherein the immunostimulatory nucleic acid is further defined as an oligodeoxynucleotide containing deoxyinosine, an oligodeoxynucleotide containing deoxyuridine, an oligodeoxynucleotide containing at least one CG motif, or an inosine and cytidine containing nucleic acid molecule.

5. A pharmaceutical composition comprising at least one antigen and a peptide consisting of the sequence H—KLKLLLLLKLK—H (SEQ ID NO: 1).

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Nov 10, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: VALNEVA AUSTRIA GMBH; VALNEVA SE; VALNEVA USA, INC.
Reel/Frame 073516/0522 →
PATENT SECURITY AGREEMENT Recorded Oct 20, 2025
From: VALNEVA AUSTRIA GMBH; VALNEVA SE; VALNEVA SWEDEN AB
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 073164/0032 →
SECURITY INTEREST Recorded Mar 4, 2020
From: VALNEVA SE; VALNEVA USA, INC.; VALNEVA AUSTRIA GMBH
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 052016/0745 →